Featured Article
Better cardiovascular risk models for women have been developed using a large dataset of more than 20,000 participants in the UK Biobank.
Precision Oncology Today
Magazine
Beginning a New Era of Precision Alzheimer’s Therapeutics
Alzheimer’s is a disease associated with aging and impacts almost seven million people in the U.S. over the age of 65, with women and Black or Hispanic populations disproportionately affected by the condition. Finding an effective treatment for Alzheimer’s disease has proved to be a long and difficult quest.
5 Startups With Proteomics Potential Attracting Investor Cash
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics...
Trending on Inside Precision Medicine
Removing Notch Ligand, Jagged2, Rewires the Immune System to Eliminate NSCLC
Removing Jagged2, a molecule in the Notch signaling pathway, stimulates the spread of macrophages to eliminate non-small cell lung cancer (NSCLC) cells.
Day One’s Targeted Treatment for Most Common Kid’s Brain Tumor Approved
The FDA has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
UCSF Launches Clinical Trial on New CAR T Therapy for Glioblastoma
Researchers at the University of California, San Francisco (UCSF) have begun enrollment for a clinical trial that uses a new, powerful version of CAR T as a potential therapy for glioblastoma.